BridgeBio publishes Phase 3 CALIBRATE trial presentation for encaleret in ADH1

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • BridgeBio published primary Phase 3 CALIBRATE results for encaleret in autosomal dominant hypocalcemia type 1.
  • Primary composite endpoint met in 75.6% of participants randomized to encaleret, defined as albumin-corrected serum calcium 2.08-2.68 mmol/L with 24-hour urine calcium within reference range.
  • Restoration of endogenous intact PTH to at least 1.6 pmol/L reached 91.1% in encaleret group.
  • Between-treatment comparisons versus standard of care showed statistically significant improvements in corrected calcium, 24-hour urine calcium, intact PTH.
  • No treatment-emergent adverse events led to encaleret or study discontinuation; hypercalcemia reported in 22.2% of encaleret-treated participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.